Tous Actualités
Suivre
Abonner PharmaMar

PharmaMar

PharmaMar Reinforces its Clinical Development Team With the Appointment of Dr Pedro Santabárbara

Madrid (ots/PRNewswire)

- In his Previous Position he was Vice President, Clinical
Research  Oncology at OSI Pharmaceuticals in the US
PharmaMar announced today the appointment of Dr. Pedro
Santabárbara  as Senior Director of the Clinical Development
Department. Dr. Santabárbara  is a medical oncologist trained at the
University Hospital of Barcelona,  with wide international experience
in the pharmaceutical and biotechnology  industry, including
management positions in Clinical Oncology Research  Departments at
Bristol Myers, Rhône Poulenc Rhorer, Ilex Oncology and  OSI
Pharmaceuticals. For the last 13 years he has been closely involved
in the clinical development and approval of the important drugs
currently used in the treatment of cancer, such as Taxotere, Campath
and Tarceva.
He will focus on the clinical development and regulatory
strategies for all compounds in PharmaMar`s clinical pipeline.
Dr. Miguel Ángel Izquierdo, PharmaMar's Director of the Clinical
Development Area, commented: "Dr. Pedro Santabárbara's appointment is
excellent news for PharmaMar. His experience in key positions in
multinational companies and his direct involvement in the approval of
various anti-tumour drugs is very valuable for us. In addition, his
appointment is very timely since we are now at the clinical
development stage for five drugs and are preparing the registration
dossier for Yondelis for the treatment of soft tissue sarcoma."
Currently, the Clinical Development Area at PharmaMar has over 50
professionals, including a team of eight medical oncologists. In May
this year, Dr Cesar Picó joined PharmaMar as Director of Clinical
Oncology. He has more than 13 years of experience in several
University Hospitals as well as in the Pharmaceutical Industry as
Medical Oncology Consultant at Pharmacia Upjohn and subsequently at
Pfizer. He is also a founding member of the Spanish Breast Cancer
Research Group (GEICAM).
These new appointments represent a considerable strengthening of
the PharmaMar Clinical Development Team.
About PharmaMar
PharmaMar is the world's leading biopharmaceutical companies in
advancing cancer care through the discovery and development of
innovative marine-derived medicines. PharmaMar's clinical portfolio
currently includes: YONDELIS(TM) (co-developed with Johnson & Johnson
Pharmaceutical Research & Development) in Phase III clinical trials;
it is also designated Orphan Drug for Soft Tissue Sarcomas by the
European Commission (E.C.) in 2001 and by the FDA in 2004, and Orphan
Drug for ovarian cancer by the E.C. in 2003 and by the FDA in 2005.
It also features Aplidin(R), in Phase II, designated Orphan Drug for
acute lymphoblastic leukaemia by the E.C. in 2003 and by the FDA in
2004, and for multiple myeloma by the FDA and the EC in 2004; as well
as Kahalalide F in Phase II, and ES-285 and Zalypsis(R) in Phase I
clinical trials.
PharmaMar, based in Madrid, Spain, is a subsidiary of the Zeltia
Group (Spanish stock exchange, ZEL).
    For more information, contact:
    Media:     Lola Casals, PharmaMar Communication (tel.: +34-91-846-6000)
    Investors: Catherine Moukheibir, Zeltia Capital Markets Operations
    (tel.: +34-91-444-4500)
MADRID, July 11 /PRNewswire/ --
This press release is also available in the News section on
PharmaMar's web site: http://www.pharmamar.com/en/press/

Contact:

For more information, contact: Media: Lola Casals, PharmaMar
Communication (tel.: +34-91-846-6000); Investors: Catherine
Moukheibir, Zeltia Capital Markets Operations; (tel.:
+34-91-444-4500)

Plus de actualités: PharmaMar
Plus de actualités: PharmaMar
  • 17.01.2005 – 08:25

    PharmaMar's Fifth Novel Compound, Zalypsis(R), Enters Clinical Development

    Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs ...

  • 25.11.2004 – 08:32

    Aplidin(R) Enters Phase II Trials in Haematological Cancers

    Madrid, Spain, November 25 (ots/PRNewswire) - - Aplidin(R) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in haematological malignancies, including studies in Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) ...